Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Quarterly Basic Net EPS At 2016-03-31

0

For the year ended 2016-03-31 Xenon Pharmaceuticals Inc. (NASDAQ:XENE) basic consolidated EPS came $-1.1029. Conversely, for the quarter ended 2016-03-31, it was $-1.1029.

EPS can be simply called as a fraction of profits that is disbursed against each outstanding share. It is measured using the formula – net profit/outstanding shares. The element ‘Per-share earnings’ is majorly utilized by market experts to give earnings and price projections. Suppose a group “S” announces a net profit of $15,000 in a given year. The count of outstanding shares is 300. So, its EPS will be $50. EPS is issued every quarter, indicating the stakeholders can evaluate the financial performance periodically.

EPS alone cannot indicate on the financial well-being of a firm. For a clear picture, it is vital to look into the price to earnings ratio of company.

EPS from continuing operations

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) EPS from continuing operations was $-1.1029 for the fiscal ended 2016-03-31. For the quarter ended 2016-03-31, this figure was $-1.1029.

EPS contribution from parent

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) confirmed basic EPS of $-1.1029 for the year ended 2016-03-31 from its parent group. Conversely, for the quarter closed 2016-03-31 it was $-1.1029.

Basic net EPS

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) basic net EPS was $-0.23 for the year ended 2016-03-31. For the quarter ended 2016-03-31, it came at $-0.23.

Consolidated diluted EPS

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) consolidated diluted EPS was -1.1029 for the year ended 2016-03-31. For the quarter ended 2016-03-31, it stood at $-1.1029.

Basic diluted EPS

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) basic diluted EPS was $-0.2267 for the quarter ended 2016-03-31. For the year ended 2016-03-31, basic diluted EPS was $-0.2267.

Net diluted EPS

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) posted net diluted EPS of $-1.1 for the fiscal closed 2016-03-31. For the quarter ended 2016-03-31, net diluted EPS was $-1.1.

Diluted EPS from parent

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) diluted EPS from parent group was $-1.1029 for the year ended 2016-03-31. For the quarter ended 2016-03-31 it stood at $-1.1029.

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) net basic EPS was $4.11 for the year ended 2016-03-31. For the quarter ended 2016-03-31, it was $4.11.

For the year ended 2016-03-31, basic shares outstanding were 3.166 while for the quarter ended 2016-03-31 is 3.166.

For the fiscal ended 2016-03-31, the diluted outstanding shares were 3.964 and for the quarter ended 2016-03-31 it was 3.964.

1 Chart Pattern Every Investor Should Know

This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...

Click Here to See This Now.

(Visited 4 times, 1 visits today)